Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
暂无分享,去创建一个
J Verweij | J. Verweij | H. Gelderblom | A. Sparreboom | A Sparreboom | K Nooter | K. Nooter | H Gelderblom
[1] J. Barré,et al. Problems in therapeutic drug monitoring: free drug level monitoring. , 1988, Therapeutic drug monitoring.
[2] N. Gleicher,et al. Cytotoxic effects of free fatty acids on ascites tumor cells. , 1987, Journal of the National Cancer Institute.
[3] J. Verweij,et al. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. , 1998, Analytical biochemistry.
[4] A. G. Ellis,et al. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL , 1999, Cancer Chemotherapy and Pharmacology.
[5] S. Brimijoin,et al. Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. , 1992, The Journal of pharmacology and experimental therapeutics.
[6] J. Verweij,et al. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] G. Forbes,et al. Central Nervous System Toxicity after Liver Transplantation , 1987 .
[8] J. Bergh,et al. Is Cremophor EL, solvent for paclitaxel, cytotoxic? , 1993, The Lancet.
[9] Mark L. Greenberg,et al. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] G. Giaccone,et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Bonadonna,et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] F. Hamada,et al. Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[13] J. Verweij,et al. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] M. Millward,et al. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. , 1993, Journal of the National Cancer Institute.
[15] A. Weinstein,et al. Unusual serum lipoprotein abnormality induced by the vehicle of miconazole. , 1977, The New England journal of medicine.
[16] J. Bergh,et al. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. , 1995, British Journal of Cancer.
[17] R S Weinstein,et al. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. , 1991, Cancer research.
[18] J B Vermorken,et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] V. Ling,et al. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. , 1993, Cancer research.
[20] B. Williams,et al. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. , 1990, Cancer research.
[21] W. Sawyer,et al. Reversal of multidrug resistance by surfactants. , 1992, British journal of cancer.
[22] J Verweij,et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.
[23] A. Windebank,et al. Potential neurotoxicity of the solvent vehicle for cyclosporine. , 1994, The Journal of pharmacology and experimental therapeutics.
[24] J. Böhler,et al. Titrimetric determination of Cremophor EL in aqueous solutions and biofluids: part 2: ruggedness of the method with respect to biofluids. , 1999, Journal of pharmaceutical and biomedical analysis.
[25] J Verweij,et al. Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients , 2000, Anti-cancer drugs.
[26] B. Leyland-Jones,et al. Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Kessel,et al. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. , 1994, British Journal of Cancer.
[28] J. Verweij,et al. Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes , 1996, Cancer Chemotherapy and Pharmacology.
[29] J. W. Wilson,et al. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. , 1993, Journal of the National Cancer Institute. Monographs.
[30] J. Beijnen,et al. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. , 1996, Journal of chromatography. B, Biomedical applications.
[31] G. Volcheck,et al. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[32] J. Beijnen,et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. , 1996, Cancer research.
[33] J. B. Vermorken,et al. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. , 1990, British Journal of Cancer.
[34] D. Kessel,et al. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal. , 1995, Oncology research.
[35] D. Horrobin,et al. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. , 1988, Journal of the National Cancer Institute.
[36] H. Pinedo. Development of new anti-cancer drugs , 1986, Medical oncology and tumor pharmacotherapy.
[37] A. McPhail,et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.
[38] D. Kessel,et al. The alteration of plasma lipoproteins by cremophor EL. , 1994, Journal of photochemistry and photobiology. B, Biology.
[39] J. Beijnen,et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[40] P. Sonneveld,et al. Clinical relevance of P-glycoprotein expression in haematological malignancies. , 1994, Leukemia research.
[41] M. Millward,et al. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. , 1996, Journal of the National Cancer Institute.
[42] J. Kigawa,et al. Effects of Taxol on blood cells , 1998, The Lancet.
[43] B. Williams,et al. Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil. , 1995, International journal of radiation biology.
[44] R. Larsson,et al. Differential activity of cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro , 1997, Cancer.
[45] F M Muggia,et al. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. , 1998, Journal of the National Cancer Institute.
[46] J. Verweij,et al. Measurement of fraction unbound paclitaxel in human plasma. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[47] D M Woodcock,et al. Phase I trial of cremophor EL with bolus doxorubicin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] J. L. Biedler,et al. Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. , 1972, Cancer research.
[49] G. Giaccone,et al. Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients , 2000, Anti-cancer drugs.
[50] E K Rowinsky,et al. Cardiac disturbances during the administration of taxol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J. Verweij,et al. Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. , 1998, Analytical biochemistry.
[52] J. Watkins,et al. Adverse reactions to intravenous anaesthetic induction agents. , 1977, British medical journal.
[53] M. Sehested,et al. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. , 1990, Cancer communications.
[54] G. Hortobagyi,et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] E K Rowinsky,et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] J. Verweij,et al. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[57] E. Eisenhauer,et al. Clinical toxicities encountered with paclitaxel (Taxol). , 1993, Seminars in oncology.
[58] J. Beijnen,et al. Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use-A Review , 1996 .
[59] A. Olesen,et al. Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR). , 1980, British journal of anaesthesia.
[60] J Moan,et al. Interaction of cremophor EL with human plasma. , 1991, International Journal of Biochemistry.
[61] J. Verweij,et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[62] M. Brecher,et al. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. , 1993, Anticancer research.
[63] Takashi Tsuruo,et al. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models , 1996, Anti-cancer drugs.
[64] E. Warner,et al. Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] J. Verweij,et al. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[66] K. Osann,et al. Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. , 1995, Leukemia research.